3 documents found, page 1 of 1
Global impact of the COVID-19 pandemic on stroke volumes and cerebrovascular ev...
Nguyen, Thanh N.; Qureshi, Muhammad M.; Klein, Piers; Yamagami, Hiroshi; Mikulik, Robert; Czlonkowska, Anna; Abdalkader, Mohamad; Sedova, PetraBackground and objectives: Declines in stroke admission, IV thrombolysis (IVT), and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the effect of the COVID-19 pandemic on the volumes of str...
Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocyto...
Krzywicka, Katarzyna; van de Munckhof, Anita; Zimmermann, Julian; Bode, Felix J.; Frisullo, Giovanni; Karapanayiotides, Theodoros; Pötzsch, BerndCerebral venous thrombosis (CVT) is the most common and severe manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT), which is a rare side effect of the SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca/Oxford). The absolute risk of VITT and VITT-related CVT is estimated at 20 and 8 per million first doses of ChAdOx1 nCoV-19, respectively. So far, no definite VITT cases occurring a...
Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination
Scutelnic, Adrian; Krzywicka, Katarzyna; Mbroh, Joshua; van de Munckhof, Anita; van Kammen, Mayte Sánchez; de Sousa, Diana Aguiar; Lindgren, ErikObjective: Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance...